In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 42 for your search:

Drug:  ipilimumab
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX010-20, CA184-002, NCT00094653

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-024, NCT00324155

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-029, EORTC 18071, NCT00636168

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-169, 2011-004029-28, NCT01515189

Phase I/II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-CTLA4) and High-Dose Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-03-C-0109, NCT00058279

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000378036, R21CA108182, P30CA015083, U01CA069912, MC0312, 6359, 0406055-01, MAYO-MC0312, NCI-6359, UCLA-0406055-01, NCT00089076

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX010-21, CA184-017, NCT00323882

Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) Combined With gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-02-C-0106H, NCI-5743, 5743, NCT00032045

Phase II Pilot Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-CTLA4) in Patients With Follicular or Mantle Cell Lymphoma, Colon Cancer, Prostate Cancer Refractory to Vaccine Therapy (Prostate cancer and mantle cell lymphoma closed to accrual as of 3/10/2005; colon cancer closed to accrual as of 9/28/05),Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-02-C-0284, NCI-5744, NCT00047164, 5744

10.

Phase II Randomized Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) With or Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0083, MDX-010-19, NCI-6532, 6532, NCT00077532

11.

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX010-07, CA184-019, NCT00050596

12.

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000365467, P30CA076292, P30CA014089, MCC-15241, MDX010-16, NCI-6446, CA184-016, 6446, LAC-USC-10M036, NCT00084656

13.

Study of MDX-010 in Stage IV Breast Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX010-12, CA184-015, NCT00083278

14.

Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) in Patients With Unresectable Stage IV (Locally or Distantly Metastatic) Pancreatic Adenocarcinoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-05-C-0141, NCI-P6557, MDX-010-24, NCT00112580

15.

MDX-010 for Advanced Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MC0253, 1564-02, NCT00170157

16.

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-008, NCT00289627

17.

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-022, NCT00289640

18.

Phase II Randomized Study of Ipilimumab With Versus Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Previously Treated, HLA-A*0201 Positive Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-06-C-0159, NCI-P6951, MDX-NCI-06-C-0159, NCT00357461

19.

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Status: Closed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-025, NCT00162123

20.

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-007, NCT00135408

21.

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-041, NCT00527735

22.

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-125, NCT00610857

23.

Study of Ipilimumab to Treat Melanoma in Patients With Brain Metastases

Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-042, NCT00623766

24.

Phase II Randomized Study of Ipilimumab With Versus Without Sargramostim in Patients With Unresectable or Metastatic Stage III or IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1608, E1608, NCT01134614

25.

Ipilimumab + Temozolomide in Metastatic Melanoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2009-0408, NCT01119508

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®